Worldwide delivery in 2 to 3 business days. Shipping details

alphapeptide

Tirzepatide: research overview

Dual GIP/GLP-1 co-agonist with biased GIPR activity; once-weekly SC dosing via C20-diacid albumin binding.

GLP-1 analogue. Molecular weight 4,813.53 Da; half-life 5 d. Reference material compiled from the published literature. For laboratory research only; nothing on this page is medical advice or a claim about a product.

How it is studied

Tirzepatide is a 39-residue dual GIP/ receptor co-agonist based on the GIP backbone with Aib substitutions at positions 2 and 13 and a C20 fatty-diacid attached at Lys20 for albumin binding. It activates GIPR with near-native affinity but binds GLP-1R approximately 5-fold weaker than native , making it an imbalanced co-agonist biased toward GIPR. Downstream Gαs-cAMP signaling at both receptors enhances glucose-dependent insulin secretion, slows gastric emptying, and engages hypothalamic appetite circuits.

Tirzepatide (LY3298176) is Eli Lilly's first-in-class dual incretin agonist, combining GIP and receptor activation in a single 39-amino-acid scaffold. Its imbalanced pharmacology — full GIPR activity with attenuated GLP-1R signaling — produced unprecedented weight-loss magnitudes in SURMOUNT trials, making it the leading benchmark for current and next-generation polyagonist research.

Half-life, with its caveats

~5 days (~117 h) in humans SC. Two-compartment PK; 99% albumin-bound via C20 fatty-diacid linker at Lys20. Schneck et al., CPT: Pharmacometrics 2024; Mounjaro FDA label.

How to read this page

  • Mechanism describes what the published studies tested, not what a product does.
  • Reported research areas list where the compound has been studied. They are not indications.
  • Dose ranges are what the literature reports, quoted for reference. They are not dosing advice.
  • Co-factor studies carry PubMed citations; open the source before relying on a figure.
Co-factors

Compounds studied alongside it

Moderate evidence

Compounds identified in published research as sharing pathways with Tirzepatide, or studied alongside it in trials. Reference material only — not a recommendation, not medical advice. Citations link to PubMed.

Dietary protein (with resistance training)

Whole-food protein
Shared mechanism

Pharmacologic weight loss drives lean mass loss alongside fat loss; protein supplies amino acid substrate, resistance training potentiates muscle protein synthesis

Tirzepatide produces some of the largest weight reductions in the incretin class (up to ~22.5% in SURMOUNT-1), and approximately 25% of that lost weight is reported as lean mass in published analyses. The post hoc analysis of SURMOUNT-1-4 by Almandoz and colleagues found rare clinical malnutrition events but specifically noted that routine vitamin and mineral surveillance was not collected in the trials, limiting micronutrient conclusions. Reviews of GLP-1 RA sarcopenia again identify high protein intake and resistance training as the principal nutritional levers studied alongside the drug class.

CitationsPMID 416406752026PMID 402890602025

Vitamin B12 (cobalamin)

Methylcobalamin or cyanocobalamin
Shared mechanism

Delayed gastric emptying reduces food-bound B12 release; concurrent metformin compounds ileal absorption interference

Tirzepatide shares the dual GLP-1/GIP delayed-gastric-emptying mechanism that drives the broader incretin-class cobalamin signal. The Urbina 2026 narrative review reports thiamine and cobalamin deficits that increase over time in pooled GLP-1 RA users (a category that includes tirzepatide cohorts in the underlying observational datasets). In type 2 diabetes, tirzepatide is also routinely combined with metformin, where the metformin-B12 depletion relationship is well established in long-term DPPOS data and a 2016 meta-analysis. Studied through deficiency surveillance, not dedicated tirzepatide supplementation RCTs.

CitationsPMID 415499122026PMID 269006412016

Magnesium

Magnesium chloride, glycinate, or citrate
Shared mechanism

Magnesium is a cofactor in insulin signaling and tyrosine kinase activity; deficiency is over-represented in the type 2 diabetes population tirzepatide is prescribed for

Tirzepatide is used predominantly in populations with insulin resistance (type 2 diabetes, obesity). Magnesium deficiency is well-documented to worsen insulin sensitivity in those populations, and oral magnesium supplementation has been reported in a 2004 placebo-controlled trial to improve HOMA-IR in hypomagnesemic non-diabetic insulin-resistant subjects (from 4.6 to 2.6) and in a 2017 meta-analysis to improve fasting glucose, HDL, LDL, triglycerides and systolic blood pressure in type 2 diabetes. The shared population — insulin-resistant adults with high magnesium-deficiency prevalence — makes magnesium status a documented co-factor for the pathway tirzepatide is targeting, even though direct co-administration RCTs with tirzepatide are not published.

CitationsPMID 152239772004PMID 281503512017
Caveat

Tirzepatide cofactor evidence is partly subsumed in pooled GLP-1 RA analyses. The Almandoz SURMOUNT post hoc explicitly notes the absence of routine micronutrient measurement in the pivotal trials, so direct tirzepatide micronutrient data is thinner than the broader class data suggests.

All reading

Subscribe to our newsletter and enjoy 10% off

New products, restocks and offers. Your code is shown straight away and emailed to you. Unsubscribe with one click.

Analytics cookies

With your permission we use Google Analytics to see which pages and products are useful. It sets cookies. Our own measurement is cookieless and runs either way. Details in the cookie policy.